MISSISSAUGA, ONTARIO -- (MARKET WIRE) -- September 25, 2006 -- BioSyent Inc. (“BioSyent”) (TSX VENTURE: RX) subsidiary BioSyent Pharma Inc. is pleased to announce that it is launching FeraMAX™, an oral hematinic, to the Canadian healthcare market via pharmaceutical wholesalers and retail pharmacies. FeraMAX™ helps the body form red blood cells and is indicated for the prevention and treatment of iron deficiency anemia (IDA). It is formulated with polysaccharide-iron complex (PIC), which provides a non-ionic delivery system that allows the iron ion to be delivered to the bloodstream without coming in to contact with the stomach or upper gastro-intestinal tract. This non-ionic formulation leads to improved iron absorption by the body and eliminates adverse side effects such as nausea, constipation, diarrhea, and epigastric pain associated with many other iron formulations.
